Insights

Why Novavax Stock Is Jumping Today

What happened
Shares of Novavax (NASDAQ: NVAX) were jumping 3.1% as of 10:01 a.m. ET on Wednesday after rising as much as 11.3% earlier in the day. The move came after a U.S. Food and Drug Administration (FDA) advisory committee voted 21-0 with one abstention on Tuesday in favor of recommending Emergency Use Authorization (EUA) for Novavax’s COVID-19 vaccine NVX-CoV2373.
So what
The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) concluded that the benefits of NVX-CoV2373 outweighed any potential risks. One of those risks was highlighted in the FDA’s briefing documents released last week. The data for NVX-CoV2373 revealed multiple adverse events of myocarditis (inflammation of the heart). 
Some investors were worried about the possible impact on Novavax’s prospects with the advisory committee’s deliberations. The vaccine stock plunged close to 20% at one point last week.
However, the FDA’s briefing documents stated that there wasn’t enough data to conclude that Novavax’s vaccine caused the cases of myocarditis. The VRBPAC didn’t appear to be overly concerned in light of the very low number of adverse events and the solid efficacy for NVX-CoV2373.
Image source: Getty Images.

Importantly, Novavax noted in its announcement of the advisory committee’s decision that the overall rate of myocarditis was similar between the groups of patients receiving NVX-CoV2373 and a placebo. The company also stated that “in the post-crossover portions of Novavax trials the observed cases were all within the expected rate.”
Now what
The FDA must now make its official decision on EUA for NVX-CoV2373 in adults ages 18 and older. Although the agency doesn’t have to go along with the advisory committee’s recommendation, it seems likely to do so. 
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. –

What happened

Shares of Novavax (NASDAQ: NVAX) were jumping 3.1% as of 10:01 a.m. ET on Wednesday after rising as much as 11.3% earlier in the day. The move came after a U.S. Food and Drug Administration (FDA) advisory committee voted 21-0 with one abstention on Tuesday in favor of recommending Emergency Use Authorization (EUA) for Novavax’s COVID-19 vaccine NVX-CoV2373.

So what

The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) concluded that the benefits of NVX-CoV2373 outweighed any potential risks. One of those risks was highlighted in the FDA’s briefing documents released last week. The data for NVX-CoV2373 revealed multiple adverse events of myocarditis (inflammation of the heart). 

Some investors were worried about the possible impact on Novavax’s prospects with the advisory committee’s deliberations. The vaccine stock plunged close to 20% at one point last week.

However, the FDA’s briefing documents stated that there wasn’t enough data to conclude that Novavax’s vaccine caused the cases of myocarditis. The VRBPAC didn’t appear to be overly concerned in light of the very low number of adverse events and the solid efficacy for NVX-CoV2373.

Image source: Getty Images.

Importantly, Novavax noted in its announcement of the advisory committee’s decision that the overall rate of myocarditis was similar between the groups of patients receiving NVX-CoV2373 and a placebo. The company also stated that “in the post-crossover portions of Novavax trials the observed cases were all within the expected rate.”

Now what

The FDA must now make its official decision on EUA for NVX-CoV2373 in adults ages 18 and older. Although the agency doesn’t have to go along with the advisory committee’s recommendation, it seems likely to do so. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex Securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

FREE AAPL, TSLA, AMZN, PFE or MRO Share(s)
REGISTER TO BE ELIGIBLE FOR FREE SHARES
TRAVEL ACROSS THE FINANCIAL WORLD
Act Fast - Promotion Ends In
Click Here To Get Started
FREE AAPL, TSLA, AMZN, PFE or MRO Share(s)
REGISTER TO BE ELIGIBLE FOR FREE SHARES
TRAVEL ACROSS THE FINANCIAL WORLD
Act Fast - Promotion Ends In
Click Here For More Info